EMJ Oncology 10 [Supplement 5] . 2022

In this issue

Identifying the genomic alterations in non-small cell lung cancer (NSCLC) can allow healthcare professionals to make the most suitable treatment decisions for patients. A common mutation associated with NSCLC involves mesenchymal-epithelial transition (MET). Understanding the MET mutation, and other genomic mutations associated with NSCLC, can help develop more effective personalised treatment.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.